Sign In
Buy GH
$127.03
-3.14 (-2.41%)
At Close: Jun 03, 2026
Guardant Health (GH) Moves 6.9% Higher: Will This Strength Last?
06:20am, Tuesday, 30'th Jul 2024
Guardant Health (GH) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down t
Guardant Health Gets FDA Nod on Colorectal Cancer Blood Test
02:57pm, Monday, 29'th Jul 2024
Guardant Health (GH) on Monday said that its Shield colorectal cancer-screening blood test has received approval from the U.S. Food and Drug Administration (FDA), sending shares higher.
FDA Greenlights Guardant Health's Shield Blood Test, Analyst Cautious on Adoption
01:21pm, Monday, 29'th Jul 2024
On Monday, the FDA approved Guardant Health Inc.'s GH Shield blood test for colorectal cancer (CRC) screening in adults age 45 and older who are at average risk for the disease.
Guardant Health Shares Rise 7% After FDA Approves Its Blood Test For Colon Cancers
10:01am, Monday, 29'th Jul 2024
Shares of Guardant Health jumped 7% on Monday, after the Food and Drug Administration approved the company's blood test to screen for colon cancer, a new testing method the company said is intended to
US FDA approves Guardant Health's blood-based cancer test
06:41am, Monday, 29'th Jul 2024
The U.S. Food and Drug Administration on Monday approved Guardant Health's blood test to detect a cancer that starts in the colon or rectum.
PALO ALTO, Calif.--(BUSINESS WIRE)--The FDA has approved the Shield test from Guardant Health, the first blood test approved as a primary screening option for colorectal cancer.
3 Precision Medicine Stocks Tailoring Treatments
06:00am, Sunday, 21'st Jul 2024
Two elements favor the case for acquiring precision medicine stocks. First, the obvious point: barring extraordinary circumstances, the broader healthcare ecosystem will always be relevant.
Dr. Manuel Hidalgo Medina Joins Guardant Health Board of Directors
05:00pm, Thursday, 18'th Jul 2024
PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (NASDAQ:GH), a pioneer in precision oncology, today announced the appointment of Dr. Manuel Hidalgo Medina to its board of directors, effectiv
The 3 Best Personalized Medicine Stocks to Buy in July 2024
07:00am, Wednesday, 03'rd Jul 2024
The personalized medicine market is experiencing significant growth, driven by advancements in genomic technologies and a shift towards more individualized healthcare. In 2024, the market is expected
From ‘Sell' to ‘Strong Buy': 3 Dramatic Analyst U-Turns to Watch
06:15am, Tuesday, 02'nd Jul 2024
The bottom line about the stock market is that it is a popularity contest. That's because there is no one true way to determine the exact value of a stock.
Guardant Health (GH) Just Overtook the 20-Day Moving Average
10:35am, Wednesday, 26'th Jun 2024
After reaching an important support level, Guardant Health (GH) could be a good stock pick from a technical perspective. GH surpassed resistance at the 20-day moving average, suggesting a short-term b
Guardant Health (GH) Now Trades Above Golden Cross: Time to Buy?
10:55am, Tuesday, 25'th Jun 2024
After reaching an important support level, Guardant Health, Inc. (GH) could be a good stock pick from a technical perspective. GH recently experienced a "golden cross" event, which saw its 50-day simp
PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (NASDAQ:GH), a leading precision oncology company, today announced the launch of a new version of its Guardant360 TissueNext test that expands
Guardant Health Named to TIME100 Most Influential Companies
08:05am, Friday, 31'st May 2024
PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (NASDAQ:GH), a leading precision oncology company, today announced its inclusion in the fourth-annual TIME100 Most Influential Companies list,
PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company and its research collaborators will present data from 16 studi
